Methylation and liver cancer

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 6, 2013, Pages 564-571

  Raggi, Chiara ^a   Invernizzi, Pietro ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; ZEBULARINE;

BILE DUCT CARCINOMA; CANCER STEM CELL; CPG ISLAND; DEREGULATION; DNA METHYLATION; DNA SEQUENCE; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; SHORT SURVEY; STEM CELL;

BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CPG ISLANDS; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; METHYLTRANSFERASES; NEOPLASTIC STEM CELLS; RNA, UNTRANSLATED;

EID: 84888430321     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.05.009     Document Type: Short Survey

References (74)

1. Bosch F.X., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5 Suppl.1):S5-S16.
2. Parkin D.M., et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer 2010, 127(12):2918-2927.
3. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48(1):308-321.
4. Shaib Y., El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24(2):115-125.
5. El-Serag H.B. Hepatocellular carcinoma. N Engl J Med 2011, 365(12):1118-1127.
6. Kumar M., Zhao X., Wang X.W. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?. Cell Biosci 2011, 1(1):5.
7. Liu W.R., et al. Epigenetics of hepatocellular carcinoma: a new horizon. Chin Med J (Engl) 2012, 125(13):2349-2360.
8. Bird A. Perceptions of epigenetics. Nature 2007, 447(7143):396-398.
9. Berger S.L., et al. An operational definition of epigenetics. Genes Dev 2009, 23(7):781-783.
10. Huang J. Current progress in epigenetic research for hepatocarcinomagenesis. Sci China C Life Sci 2009, 52(1):31-42.
11. Huang J., et al. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 2010, 120(1):223-241.
12. Niu D., et al. HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Mol Oncol 2009, 3(1):67-76.
13. Seok J.Y., et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 2012, 55(6):1776-1786.
14. Marquardt J.U., et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 2011, 54(3):1031-1042.
15. Wang M., et al. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer 2011, 128(1):72-81.
16. Wang M., et al. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. Int J Cancer 2011, 128(8):1996-1997.
17. O'Brien C.A., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123):106-110.
18. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
19. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7(1):21-33.
20. Munoz P., Iliou M.S., Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012, 6(6):620-636.
21. Lister R., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462(7271):315-322.
22. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321(6067):209-213.
23. Smiraglia D.J., et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001, 10(13):1413-1419.
24. Jurkowska R.Z., Jeltsch A. Silencing of gene expression by targeted DNA methylation: concepts and approaches. Methods Mol Biol 2010, 649:149-161.
25. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16(1):6-21.
26. Reik W., Kelsey G., Walter J. Dissecting de novo methylation. Nat Genet 1999, 23(4):380-382.
27. Liang G., et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002, 22(2):480-491.
28. Baylin S.B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005, 2(Suppl.1):S4-S11.
29. Sawan C., et al. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res 2008, 642(1-2):1-13.
30. Baylin S.B., Chen W.Y. Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 2005, 70:427-433.
31. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
32. Lee K.D., et al. Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells. Biochem Biophys Res Commun 2012, 422(4):578-585.
33. Zhu J. DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006, 13(4):265-273.
34. Hamilton J.P. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics 2010, 2(2):233-243.
35. Hernandez-Vargas H., et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010, 5(3):e9749.
36. Calvisi D.F., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007, 117(9):2713-2722.
37. Tischoff I., Tannapfe A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008, 14(11):1741-1748.
38. Lou C., et al. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi 2008, 30(11):831-836.
39. Shin S.H., et al. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci 2010, 25(8):1152-1159.
40. Jiang L., Chan J.Y., Fung K.P. Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012, 422(4):739-744.
41. Tsao C.M., et al. SOX1 functions as a tumor suppressor by antagonizing the WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Hepatology 2012, 56(6):2277-2287.
42. Jia Y., et al. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics 2010, 5(8):743-749.
43. Shu X.S., et al. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/beta-catenin signaling and is frequently silenced in multiple tumors. PLoS One 2011, 6(11):e27346.
44. Kaur P., et al. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol 2012, 33(2):325-336.
45. Sohn B.H., et al. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology 2010, 138(5):1898-1908.
46. Herceg Z., Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011, 727(3):55-61.
47. Sceusi E.L., Loose D.S., Wray C.J. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford) 2011, 13(6):369-376.
48. Martin M., Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med 2012, 4(1):8.
49. Sriraksa R., et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer 2011, 104(8):1313-1318.
50. Tannapfel A., et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002, 197(5):624-631.
51. Chinnasri P., et al. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma. Hum Pathol 2009, 40(6):817-826.
52. Andresen K., et al. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics 2012, 7(11):1249-1257.
53. Iwahashi S., et al. Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis. Oncol Rep 2011, 26(5):1057-1062.
54. Maruyama R., et al. Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumour Biol 2012, 33(2):277-285.
55. Wang B., et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29(12):1787-1797.
56. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
57. Wei X., et al. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 2013, 25(2):439-446.
58. Meng F., et al. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007, 282(11):8256-8264.
59. Mott J.L., et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26(42):6133-6140.
60. Lujambio A., Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007, 6(12):1455-1459.
61. Lujambio A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67(4):1424-1429.
62. Bandres E., et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009, 125(11):2737-2743.
63. Agirre X., et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009, 69(10):4443-4453.
64. Bandres E., et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009, 15(7):2281-2290.
65. Vincent A., Van Seuningen I. On the epigenetic origin of cancer stem cells. Biochim Biophys Acta 2012, 1826(1):83-88.
66. Wang Y., Lee C.G. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?. Epigenomics 2011, 3(2):235-243.
67. Leal J.A., Lleonart M.E. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 2012, [In press].
68. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51(5):1635-1644.
69. Cairo S., et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A 2010, 107(47):20471-20476.
70. Ma S., et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7(6):694-707.
71. Li H., et al. Aberrant expression of liver microRNA in chickens infected with subgroup J avian leukosis virus. Virus Res 2012, 169(1):268-271.
72. Marquardt J.U., Factor V.M., Thorgeirsson S.S. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010, 53(3):568-577.
73. Andersen J.B., et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010, 2(54):54ra77.
74. Jiang C., et al. A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells. Anticancer Res 2007, 27(6B):3783-3789.